DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0303835 A1 Gocke Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0303835 A1 Gocke Et Al US 2010O3O3835A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0303835 A1 Gocke et al. (43) Pub. Date: Dec. 2, 2010 (54) PEPTOID LIGANDS FOR ISOLATION AND Publication Classification TREATMENT OF AUTOMMUNE TCELLS (51) Int. Cl. (75) Inventors: Anne R. Gocke, Baltimore, MD A 6LX 39/395 (2006.01) (US); D. Gomika GOIN 33/53 (2006.01) Udugamasooriya, Flower Mound, CI2N 5/0783 (2010.01) TX (US); Thomas Kodadek, A6II 35/12 (2006.01) Jupiter, FL (US) A6II 35/14 (2006.01) C07K 2/00 (2006.01) Correspondence Address: A6IP37/00 (2006.01) FULBRIGHT & UAWORSK L.L.P. A6IP37/06 (2006.01) 600 CONGRESSAVE., SUITE 2400 AUSTIN, TX 78701 (US) (52) U.S. Cl. ..................... 424/178.1; 435/7.24:435/325; (73) Assignee: THE BOARD OF REGENTS OF 424/520; 424/529; 435/372.3; 435/352:435/375; THE UNIVERSITY OF TEXAS 530/300; 977/774 SYSTEM, Austin, TX (US) (21) Appl. No.: 12/789,711 (57) ABSTRACT (22) Filed: May 28, 2010 The present invention provides for the identification of autoreactive T cell populations from individuals having Related U.S. Application Data autoimmune diseases, such as multiple Sclerosis and EAE. (60) Provisional application No. 61/182,368, filed on May Peptoids recognized by autoreactive T cells can be used to 29, 2009, provisional application No. 61/260,608, identify various types of autoimmune disease, and can also be filed on Nov. 12, 2009. used to target therapies against Such populations. Screen Against 300,000 Peptoids Patent Application Publication Dec. 2, 2010 Sheet 1 of 14 US 2010/0303835 A1 Isolate CD4+ T Cells Screen Against 300,000 Peptoids FIG. 1A Patent Application Publication Dec. 2, 2010 Sheet 3 of 14 US 2010/0303835 A1 º, :::- 0 Patent Application Publication Dec. 2, 2010 Sheet 4 of 14 US 2010/0303835 A1 FIG. 1D Patent Application Publication Dec. 2, 2010 Sheet 5 of 14 US 2010/0303835 A1 Patent Application Publication Dec. 2, 2010 Sheet 6 of 14 US 2010/0303835 A1 s tex CR g cells + AG3A one W ais - ACS 2A 20 t 0.1 o 160 1000 Peptoid Concentration (M) FIG. 2B Patent Application Publication Dec. 2, 2010 Sheet 7 of 14 US 2010/0303835 A1 TG TG W T G TG 4. CD4+ CD4- CD4+ CD4 NA-R Arti-Wy2 TCR FIG. 2C Patent Application Publication Dec. 2, 2010 Sheet 8 of 14 US 2010/0303835 A1 A. MBP AC 1-1 1 CD4+ T Cels 30H AG12APeptoid Control peptoid C S. g 2 w C d U s C) 0.1 1 10 100 1000 B. B cells 60 ?a-74 .9 â40 w O CD S. 20 n 0 0.1 1 10 100 1000 C. MOG 35-55 CD4+ T cells 60 .9 D . s 40 S-N-2 w G9 9. 20 C A. 0.1 1 10 100 1000 Peptoid Concentration (uM) FIG 3A-C Patent Application Publication Dec. 2, 2010 Sheet 9 of 14 US 2010/0303835 A1 0 (!), W 0 WWW Patent Application Publication Dec. 2, 2010 Sheet 10 of 14 US 2010/0303835 A1 X light No Light as - 7 5 Patent Application Publication Dec. 2, 2010 Sheet 11 of 14 US 2010/0303835 A1 Light No Light © © FIG. 4C Patent Application Publication Dec. 2, 2010 Sheet 12 of 14 US 2010/0303835 A1 88 AG t2A-Ru2+'Ag. as a Control-Ru3. Ag. ^ No Peptoid + Ag. meter No Peptoid + No Ag. 25 Days Post-Transfer FIG. 4D Patent Application Publication Dec. 2, 2010 Sheet 13 of 14 US 2010/0303835 A1 A. 5 -- PBS/CFA -- MBPAC 1-111CFA 4 3- ---. O 5 O 15 2O 25 30 Days Post-immunization 262,144 (8') Compounds 1 O Y1 NH H2N-N-r Methoxyethylamine 1,4-Diarminobutane (Nmea) (Nys)Niys O NH 4 O rt. Cru,N Piperonylamine (R)-Methylbenzylamine (Npip) (Nmba) | \ N Fufurylamine Tryptamine (Nffa) (Ntrp) S1N NH r NH 2 Allyamine Isobutylamine (Nall) (Nieu) FIG 5A-B Patent Application Publication Dec. 2, 2010 Sheet 14 of 14 US 2010/0303835 A1 Control Peptoid / - O O O O O 2 O HN-N-N-N-N-N-N-N-N-N-) O ) O ) O O HNT2 4 HN2 '4 2 N 4 CaS FIG 6. US 2010/0303835 A1 Dec. 2, 2010 PEPTOID LIGANDS FOR ISOLATION AND able label; (b) providing a second T cell population from a TREATMENT OF AUTOMMUNE TCELLS Subject having an autoimmune disease, wherein said popula tion is labeled with a second detectable label; (c) contacting said first and second T cell populations with a plurality of said 0001. This application claims priority to U.S. Provisional candidate peptoid; and (d) assessing binding of said first and Patent Application Ser. No. 61/182,368 filed May 29, 2009 second T cell populations to said candidate peptoid, wherein and Ser. No. 61/260,608 filed Nov. 12, 2009, each of which is if said peptoid binds to said second T cell population but not incorporated herein by references in its entirety. to said first T cell population, the said peptoid is recognized 0002 This invention was made with government support by autoimmune but not healthy T cells. under grant no. NO1-HV28.185 from the National Heart, Lung and Blood Institute, and grant no. DP10D00066301 0010. The autoimmune disease may be multiple sclerosis from the National Institutes of Health. The government has or rheumatoid arthritis. The ligand or peptoid may be a 3-mer, certain rights in the invention. a 4-mer, a 5-mer, a 6-mer, a 7-mer, an 8-mer, a 9-mer or a 10-mer. The first and second labels may be fluorescent or BACKGROUND OF THE INVENTION chemiluminescent, or quantum dots. The peptoid may be bound to a Support, Such as a bead, a chip, a filter, a dipstick, 0003 1. Field of the Invention a membrane, a polymer matrix or a well. The contacting step 0004. The present invention relates generally to the fields may comprise bringing said Support into contact with said of molecular biology, immunology and medicine. More par first and second T cell populations at the same time. The T cell ticularly, it concerns the identification of peptoids that are population may comprise CD4 T cells. The subjects may be recognized by autoimmune T-cells. These peptoids can be human or murine. used to identify subjects suffering from or at risk of autoim 0011. In another embodiment, there is provided a method mune disease, as well as to target these cells for removal, of removing an autoimmune T cell from a subject Suffering inhibition or destruction. from an autoimmune disease comprising (a) providing a 0005 2. Description of Related Art ligand or peptoid that binds specifically to autoimmune T 0006. The molecular basis of many autoimmune diseases cells, wherein said ligand or peptoid is bound to a Support; (b) remains unknown. Due in part to this lack of a molecular-level contacting a T cell-containing sample from said Subject with understanding, the state of the art in the development of said Support-bound peptoid for a sufficient time to permit diagnostic agents and effective therapies for autoimmune binding of autoimmune T cells to said Support-bound ligand diseases is far from optimal. For example, there is no highly or peptoid; and (c) separating said Support from said sample. reliable serum protein marker for diagnosis of most autoim The method may further comprise returning the sample of mune diseases. Almost without exception, drugs employed to step (c) to said subject. The autoimmune disease may be treat these conditions either inhibit an event downstream of multiple sclerosis or rheumatoid arthritis. the autoimmune response itself. Such as inflammation, or 0012. The ligand or peptoid may be a 3-mer, a 4-mer, a attempt to modulate or Suppress the entire immune system 5-mer, a0-mer, a 7-mer, an 8-mer, a 9-mer or a 10-mer. The non-selectively (Hemmer & Hartung, 2007), with significant Support may be a bead, a chip, a filter, a dipstick, a membrane, undesirable side effects. For both diagnostic and therapeutic a polymer matrix or a well. The sample may be blood, cere applications, one would ideally like to have molecules that brospinal fluidorsemen. Where the sample is blood, it may be target autoreactive B cells (and the antibodies they produce) obtained from said subject, treated ex vivo, and returned to and T cells directly, but ignore B and T cells that recognize said subject, and further, the blood may be perfused across foreign antigens. Such molecules could be employed as diag said Support-bound ligand or peptoid and returned to said nostic agents and research tools for the detection and enrich subject in a closed circuit. The method may further comprise ment of autoimmune antibodies, B cells and T cells. In addi obtaining said sample from said subject. The Subject may be tion, these molecules could serve as the foundation for a novel drug development program aimed at eradicating these autore human or murine. active cells without affecting the proper function of the 0013. In still another embodiment, there is provided a method of killing an autoimmune T cell obtained from a immune system. Subject Suffering from an autoimmune disease comprising (a) 0007 Thus, there remains a need for diagnostic proce providing a ligand or peptoid that binds specifically to dures for both of these diseases that are (i) accurate and autoimmune T cells, wherein said ligand or peptoid is conju objective, (ii) simple and reproducible, and (iii) useful in both gated to a toxin; and (b) contacting a T cell-containing sample early and late stage case.
Load more

Recommended publications
  • Clostridium Species
    CLOSTRIDIUM SPECIES Prepared by Assit. Prof.Dr. Najdat B. Mahdi clostridia The clostridia are large anaerobic, gram-positive, motile rods. Many decompose proteins or form toxins, and some do both. Their natural habitat is the soil or the intestinal tract of animals and humans, where they live as harmless saprophytes. Among the pathogens are the organisms causing botulism, tetanus, gas gangrene, and pseudomembranous colitis diseases :The remarkable ability of clostridia to cause is attributed to their (1) ability to survive adverse environmental conditions through spore formation. (2) rapid growth in a nutritionally enriched, oxygen- deprived environment. (3) production of numerous histolytic toxins, and neurotoxins.and enterotoxins, Morphology & Identification . Spores of clostridia are usually wider than the diameter of the rods in which they are formed. In the various species, the spore is placed centrally, subterminally, or terminally. Most species of clostridia are motile and possess peritrichous flagella . Culture Clostridia are anaerobes and grow under anaerobic conditions; a few species are aerotolerant and will also grow in ambient air. Anaerobic culture conditions . In general, the clostridia grow well on the blood-enriched media used to grow anaerobes and on other media used to culture anaerobes as well. Clostridium botulinum Typical Organisms etiologic agents of botulism are a heterogeneous collection of large (0.6 to 1.4 × 3.0 to 20.2 μm), fastidious, sporeforming, anaerobic rods Clostridium botulinum Clostridium botulinum, which causes botulism, is worldwide in distribution; it is found in soil and occasionally in animal feces. Types are distinguished by the antigenic type of toxins they produce. Spores of the organism are highly resistant to heat, with standing 100 °C for several hours.
    [Show full text]
  • What Makes Some Bacterial Toxins So Dangerous? the Most Poisonous Substances Known
    Features Poisons and antidotes What makes some bacterial toxins so dangerous? The most poisonous substances known David Moss, Ajit Basak We are used to thinking of proteins as beneficial, so it is surprising to realize that the most toxic sub- and Claire Naylor stances known to man are also protein molecules. These are the bacterial exotoxins, proteins secreted (Birkbeck College, London) by pathogenic bacteria. Toxicity is measured by the median lethal dose (LD50). An LD50 value is defined as the mass of toxin per kg of body weight required to wipe out half of an animal population. Whereas Downloaded from http://portlandpress.com/biochemist/article-pdf/32/4/4/5064/bio032040004.pdf by guest on 02 October 2021 classic poisons, such as potassium cyanide or arsenic trioxide, have LD50 values in the range 5–15 mg/ kg, the causative agent of botulism, botulinum toxin, has an LD50 in the range 1–3 ng/kg, a million times more toxic! Highly pathogenic toxins have a catalytic ing. Treatment has to be repeated every few months. and a binding domain or subunit In the early 19th Century, it was thought that chol- era was caused by ‘bad air’. It was then discovered that Nearly all of the most potent toxins have two compo- cholera was the result of ingesting faecal-contaminated nents, A and B, that are either separate polypeptide water and we now know that the pathogenic agent is an chains or are separate domains. Component A is an 87 kDa toxin secreted by the bacterium Vibrio cholerae3,4. enzyme which modifies an important protein inside the This bacterium is the cause of many deaths in the de- host cell, whereas B is a protein that enables the toxin veloping world in the aftermath of flooding.
    [Show full text]
  • The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections
    toxins Review The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections Patience Shumba 1, Srikanth Mairpady Shambat 2 and Nikolai Siemens 1,* 1 Center for Functional Genomics of Microbes, Department of Molecular Genetics and Infection Biology, University of Greifswald, D-17489 Greifswald, Germany; [email protected] 2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, CH-8091 Zurich, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +49-3834-420-5711 Received: 20 May 2019; Accepted: 10 June 2019; Published: 11 June 2019 Abstract: Necrotizing soft tissue infections (NSTIs) are critical clinical conditions characterized by extensive necrosis of any layer of the soft tissue and systemic toxicity. Group A streptococci (GAS) and Staphylococcus aureus are two major pathogens associated with monomicrobial NSTIs. In the tissue environment, both Gram-positive bacteria secrete a variety of molecules, including pore-forming exotoxins, superantigens, and proteases with cytolytic and immunomodulatory functions. The present review summarizes the current knowledge about streptococcal and staphylococcal toxins in NSTIs with a special focus on their contribution to disease progression, tissue pathology, and immune evasion strategies. Keywords: Streptococcus pyogenes; group A streptococcus; Staphylococcus aureus; skin infections; necrotizing soft tissue infections; pore-forming toxins; superantigens; immunomodulatory proteases; immune responses Key Contribution: Group A streptococcal and Staphylococcus aureus toxins manipulate host physiological and immunological responses to promote disease severity and progression. 1. Introduction Necrotizing soft tissue infections (NSTIs) are rare and represent a more severe rapidly progressing form of soft tissue infections that account for significant morbidity and mortality [1].
    [Show full text]
  • National Resource Material Green and Black Poison Frog (Dendrobates Auratus)
    Indicative 10 Project National Resource Material Green and Black Poison frog (Dendrobates auratus) Michelle T. Christy and Win Kirkpatrick 2017 Department of Primary Industries and Regional Development 3 Baron-Hay Court, South Perth, WA 6151 An Invasive Animals CRC Project Contents Summary ............................................................................. 2 Key Messages ................................................................... 2 Classification ................................................................... 2 Common names ................................................................ 3 Biology and Ecology ................................................................ 3 Identification ................................................................... 3 Behaviours and Traits ......................................................... 4 Food and Foraging ............................................................. 4 Reproduction and Lifecycle ................................................. 5 Habitat ......................................................................... 5 Global Range ........................................................................ 5 Potential for Introduction ........................................................ 6 Potential for Eradication.......................................................... 7 Impacts ............................................................................... 7 Economic ........................................................................ 7 Environmental
    [Show full text]
  • Host-Pathogen Interactions of Secreted and Surface Staphylococcus Aureus Factors
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2010 Host-pathogen interactions of secreted and surface Staphylococcus aureus factors Vanessa Vazquez Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry Commons, and the Microbiology Commons Recommended Citation Vazquez, Vanessa, "Host-pathogen interactions of secreted and surface Staphylococcus aureus factors" (2010). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 25. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/25 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. Host-pathogen interactions of secreted and surface Staphylococcus aureus factors by Vanessa Vazquez, B.S. APPROVED: Supervisory Professor Magnus Höök, Ph.D. Burton Dickey, M.D. Theresa Koehler, Ph.D. C. Wayne Smith, M.D. Yi Xu, Ph.D. APPROVED: Dean, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences HOST-PATHOGEN INTERACTIONS OF SECRETED AND SURFACE STAPHYLOCOCCUS AUREUS FACTORS A Dissertation Presented to the Faculty of The University of Texas Health Science Center at Houston and The University of Texas M.D.
    [Show full text]
  • Introduction to Bacteriology and Bacterial Structure/Function
    INTRODUCTION TO BACTERIOLOGY AND BACTERIAL STRUCTURE/FUNCTION LEARNING OBJECTIVES To describe historical landmarks of medical microbiology To describe Koch’s Postulates To describe the characteristic structures and chemical nature of cellular constituents that distinguish eukaryotic and prokaryotic cells To describe chemical, structural, and functional components of the bacterial cytoplasmic and outer membranes, cell wall and surface appendages To name the general structures, and polymers that make up bacterial cell walls To explain the differences between gram negative and gram positive cells To describe the chemical composition, function and serological classification as H antigen of bacterial flagella and how they differ from flagella of eucaryotic cells To describe the chemical composition and function of pili To explain the unique chemical composition of bacterial spores To list medically relevant bacteria that form spores To explain the function of spores in terms of chemical and heat resistance To describe characteristics of different types of membrane transport To describe the exact cellular location and serological classification as O antigen of Lipopolysaccharide (LPS) To explain how the structure of LPS confers antigenic specificity and toxicity To describe the exact cellular location of Lipid A To explain the term endotoxin in terms of its chemical composition and location in bacterial cells INTRODUCTION TO BACTERIOLOGY 1. Two main threads in the history of bacteriology: 1) the natural history of bacteria and 2) the contagious nature of infectious diseases, were united in the latter half of the 19th century. During that period many of the bacteria that cause human disease were identified and characterized. 2. Individual bacteria were first observed microscopically by Antony van Leeuwenhoek at the end of the 17th century.
    [Show full text]
  • Staphylococcus Aureus Exfoliative Toxins: How They Cause Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE To cite this article: JID 122:1070–1077, 2004 provided by Elsevier - Publisher Connector Published by the ology Progress in Dermatology Editor: Alan N. Moshell, M.D. Staphylococcus aureus exfoliative toxins: How they cause disease. Lisa R.W. Plano, M.D., Ph.D. Departments of Pediatrics and Microbiology & Immunology University of Miami School of Medicine, Miami, Florida Abbreviations: cell surface molecules associated with adhesion and BI- bullous impetigo multiple antibiotic resistances including methicillin and ET- exfoliative toxins vancomycin resistance (Centers for Disease Control and EDIN- epidermal cell differentiation inhibitor Prevention, 1997; 2000a; 2000b), all contributing to the ETA- exfoliative toxin A (epidermolysisn A, exfoliatin A) pathogenicity of these organisms. A minimum of 34 ETB- exfoliative toxin B (epidermolysisn B, exfoliatin B) different extracellular proteins are produced by S. ETD- exfoliative toxin D (epidermolysisn D, exfoliatin D) aureus, and many of these have defined roles in the PF- pemphigus foliaceus pathogenesis of their associated diseases (Iandolo, SSSS- Staphylococcal scalded skin syndrome, (pemphi- 1989). Infectious conditions caused by these organisms gus neonatorum, dermatitis exfoliativa neonatorum, can be divided into three major categories; (i) superficial Ritter’s disease) skin infections, skin abcesses and wound infections TEN- toxic epidermal necrolysis including bullous impetigo (BI) and furuncles, (ii) systemic or infections of deep seeded tissues including osteomyelitis, endocarditis, pneumonia and sepsis, and Introduction (iii) conditions caused by intoxication with one of the General Microbiology: Staphylococci are hardy excreted toxins. Among the conditions caused by intoxi- Gram-positive cocci found as bacterial pathogens or cation with an exotoxin are toxic shock syndrome caused commensal organisms in both humans and animals.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • TETANUS in ANIMALS — SUMMARY of KNOWLEDGE Malinovská, Z
    DOI: 10.2478/fv-2020-0027 FOLIA VETERINARIA, 64, 3: 54—60, 2020 TETANUS IN ANIMALS — SUMMARY OF KNOWLEDGE Malinovská, Z., Čonková, E., Váczi, P. Department of Pharmacology and Toxicology University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 041 81 Košice Slovakia [email protected] ABSTRACT the effects of the neurotoxin. The treatment is difficult with an unclear prognosis. Tetanus is a neurologic non-transmissible disease (often fatal) of humans and other animals with a world- Key words: animal; Clostridium tetani; toxin; spasm; wide occurrence. Clostridium tetani is the spore produc- treatment ing bacillus which causes the bacterial disease. In deep penetrating wounds the spores germinate and produce a toxin called tetanospasmin. The main characteristic sign INTRODUCTION of tetanus is a spastic paralysis. A diagnosis is usually based on the clinical signs because the detection in the Of the clostridial neurotoxins, botulinum neurotoxin wound and the cultivation of C. tetani is very difficult. and tetanus neurotoxin are the most potent toxins [15]. Between animal species there is considerable variabili- Their extraordinary toxicity is caused by neurospecificity ty in the susceptibility to the bacillus. The most sensi- and metalloprotease activity, which results in the paralysis. tive animal species to the neurotoxin are horses. Sheep Tetanus is potentially a fatal disease and in some countries and cattle are less sensitive and tetanus in these animal it is still very active. Tetanus is a traumatic clostridiosis, species are less common. Tetanus in cats and dogs are an infection in humans and other animals with worldwide rare and dogs are less sensitive than cats.
    [Show full text]
  • Fibrinogen Binding Sites P336 and Y338 of Clumping Factor a Are Crucial for Staphylococcus Aureus Virulence
    Fibrinogen Binding Sites P336 and Y338 of Clumping Factor A Are Crucial for Staphylococcus aureus Virulence Elisabet Josefsson1*, Judy Higgins2, Timothy J. Foster2, Andrej Tarkowski1 1 Department of Rheumatology and Inflammation Research, University of Gothenburg, Go¨teborg, Sweden, 2 Microbiology Department, Moyne Institute of Preventive Medicine, Trinity College, Dublin, Ireland Abstract We have earlier shown that clumping factor A (ClfA), a fibrinogen binding surface protein of Staphylococcus aureus,isan important virulence factor in septic arthritis. When two amino acids in the ClfA molecule, P336 and Y338, were changed to serine and alanine, respectively, the fibrinogen binding property was lost. ClfAP336Y338 mutants have been constructed in two virulent S. aureus strains Newman and LS-1. The aim of this study was to analyze if these two amino acids which are vital for the fibrinogen binding of ClfA are of importance for the ability of S. aureus to generate disease. Septic arthritis or sepsis were induced in mice by intravenous inoculation of bacteria. The clfAP336Y338 mutant induced significantly less arthritis than the wild type strain, both with respect to severity and frequency. The mutant infected mice developed also a much milder systemic inflammation, measured as lower mortality, weight loss, bacterial growth in kidneys and lower IL-6 levels. The data were verified with a second mutant where clfAP336 and Y338 were changed to alanine and serine respectively. When sepsis was induced by a larger bacterial inoculum, the clfAP336Y338 mutants induced significantly less septic death. Importantly, immunization with the recombinant A domain of ClfAP336SY338A mutant but not with recombinant ClfA, protected against septic death.
    [Show full text]
  • Report from the 26Th Meeting on Toxinology,“Bioengineering Of
    toxins Meeting Report Report from the 26th Meeting on Toxinology, “Bioengineering of Toxins”, Organized by the French Society of Toxinology (SFET) and Held in Paris, France, 4–5 December 2019 Pascale Marchot 1,* , Sylvie Diochot 2, Michel R. Popoff 3 and Evelyne Benoit 4 1 Laboratoire ‘Architecture et Fonction des Macromolécules Biologiques’, CNRS/Aix-Marseille Université, Faculté des Sciences-Campus Luminy, 13288 Marseille CEDEX 09, France 2 Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d’Azur, CNRS, Sophia Antipolis, 06550 Valbonne, France; [email protected] 3 Bacterial Toxins, Institut Pasteur, 75015 Paris, France; michel-robert.popoff@pasteur.fr 4 Service d’Ingénierie Moléculaire des Protéines (SIMOPRO), CEA de Saclay, Université Paris-Saclay, 91191 Gif-sur-Yvette, France; [email protected] * Correspondence: [email protected]; Tel.: +33-4-9182-5579 Received: 18 December 2019; Accepted: 27 December 2019; Published: 3 January 2020 1. Preface This 26th edition of the annual Meeting on Toxinology (RT26) of the SFET (http://sfet.asso.fr/ international) was held at the Institut Pasteur of Paris on 4–5 December 2019. The central theme selected for this meeting, “Bioengineering of Toxins”, gave rise to two thematic sessions: one on animal and plant toxins (one of our “core” themes), and a second one on bacterial toxins in honour of Dr. Michel R. Popoff (Institut Pasteur, Paris, France), both sessions being aimed at emphasizing the latest findings on their respective topics. Nine speakers from eight countries (Belgium, Denmark, France, Germany, Russia, Singapore, the United Kingdom, and the United States of America) were invited as international experts to present their work, and other researchers and students presented theirs through 23 shorter lectures and 27 posters.
    [Show full text]
  • 615.9Barref.Pdf
    INDEX Abortifacient, abortifacients bees, wasps, and ants ginkgo, 492 aconite, 737 epinephrine, 963 ginseng, 500 barbados nut, 829 blister beetles goldenseal blister beetles, 972 cantharidin, 974 berberine, 506 blue cohosh, 395 buckeye hawthorn, 512 camphor, 407, 408 ~-escin, 884 hypericum extract, 602-603 cantharides, 974 calamus inky cap and coprine toxicity cantharidin, 974 ~-asarone, 405 coprine, 295 colocynth, 443 camphor, 409-411 ethanol, 296 common oleander, 847, 850 cascara, 416-417 isoxazole-containing mushrooms dogbane, 849-850 catechols, 682 and pantherina syndrome, mistletoe, 794 castor bean 298-302 nutmeg, 67 ricin, 719, 721 jequirity bean and abrin, oduvan, 755 colchicine, 694-896, 698 730-731 pennyroyal, 563-565 clostridium perfringens, 115 jellyfish, 1088 pine thistle, 515 comfrey and other pyrrolizidine­ Jimsonweed and other belladonna rue, 579 containing plants alkaloids, 779, 781 slangkop, Burke's, red, Transvaal, pyrrolizidine alkaloids, 453 jin bu huan and 857 cyanogenic foods tetrahydropalmatine, 519 tansy, 614 amygdalin, 48 kaffir lily turpentine, 667 cyanogenic glycosides, 45 lycorine,711 yarrow, 624-625 prunasin, 48 kava, 528 yellow bird-of-paradise, 749 daffodils and other emetic bulbs Laetrile", 763 yellow oleander, 854 galanthamine, 704 lavender, 534 yew, 899 dogbane family and cardenolides licorice Abrin,729-731 common oleander, 849 glycyrrhetinic acid, 540 camphor yellow oleander, 855-856 limonene, 639 cinnamomin, 409 domoic acid, 214 rna huang ricin, 409, 723, 730 ephedra alkaloids, 547 ephedra alkaloids, 548 Absorption, xvii erythrosine, 29 ephedrine, 547, 549 aloe vera, 380 garlic mayapple amatoxin-containing mushrooms S-allyl cysteine, 473 podophyllotoxin, 789 amatoxin poisoning, 273-275, gastrointestinal viruses milk thistle 279 viral gastroenteritis, 205 silibinin, 555 aspartame, 24 ginger, 485 mistletoe, 793 Medical Toxicology ofNatural Substances, by Donald G.
    [Show full text]